Structural Heart

This structural heart channel includes news, videos, podcasts and other content related to diagnosis and treatment of structural heart disease. Topics covered include heart valve repair and replacement, transcatheter aortic valve replacement (TAVR), transcatheter mitral valve replacement (TMVR), transcatheter tricuspid valve replacement (TTVR), left atrial appendage (LAA) occlusion, heart failure interventional device therapies, and closing holes in the heart using, including occlusion of atrial septal defects (ASDs), ventricular septal defects (VSDs) and patent foramen ovales (PFOs).

COVID-19 related topics by far out-paced all other topics in cardiology in 2020 on the DAIC website. Several stories topped the list related to the cardiovascular issues with hydroxychloroquine being used as a treatment for the virus. Top new device technologies in 2020 included European approval of the Abbott Tendyne transcatheter mitral valve, FDA approval of Medtronic's new Micra AV pill-sized pacemaker, and FDA clearance of the first drug-eluting stent with short-duration dual-antiplatelet therapy.
Feature | Dave Fornell, Editor
Top 25 Stories in Cardiology in 2020

Here are the top 25 best performing articles on the Diagnostic and Interventional Cardiology (DAIC) website from 2020 ...

Home December 28, 2020
Home
This year's top videos are dominated by COVID-19's impact on cardiology and many of the videos from a series produced this year on Tuft Medical Center's cardiology program. Top DAIC cardiology videos from 2020 #TuftsmedicalCenter #Tufts #COVID19
Feature | Dave Fornell, Editor
Top 25 Cardiology Videos on DAIC in 2020

Here are the top performing 25 videos on the DAIC website in 2020. The picks are based on Google Analytics of the DAIC ...

Home December 23, 2020
Home
Foldax Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted an investigational device exemption (IDE) so the company to initiate a U.S. clinical study of its Tria biopolymer mitral surgical heart valve.
News | Heart Valve Technology
Foldax to Initiate FDA Clinical Study of Biopolymer Mitral Heart Valve

December 14, 2020 - Foldax Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted an ...

Home December 14, 2020
Home
COVID-19 cardiology related content continues to be among the top performers on the DAIC website in November 2020. TAVR also topped headlines with Boston Scientific taking its Lotus valve off the market and a review of TAVR registry data showing it is now the dominant method of aortic valve replacement in the United States. #DAIC
Feature | Cardiovascular Business | Dave Fornell, Editor
Most Popular Cardiology Technology Content in November 2020

December 1, 2020 — Here is the list of the most popular content on the Diagnostic and Interventional Cardiology (DAIC) ...

Home December 01, 2020
Home
A recent publication demonstrated procedural efficiency for MitraClip transcatheter mitral valve repair (TMVR) with use of the Baylis VersaCross RF Transseptal Solution, reporting guide delivery from femoral access in under 7.5 minutes.
News | Hemodynamic Monitoring Systems
Study Finds TMVR Procedural Efficiency Using the VersaCross RF Transseptal Solution

December 1, 2020 — A recent publication demonstrated procedural efficiency for MitraClip transcatheter mitral valve ...

Home December 01, 2020
Home
RIVER trial is the largest study assessing the efficacy and safety of the anticoagulant rivaroxaban in patients with an artificial mitral valve to correct an irregular heart rhythm
News
Rivaroxaban is Comparable to Warfarin for Bioprosthetic Mitral Valves and AF

November 18, 2020 — The primary results from the RIVER Trial, Rivaroxaban for Valvular Heart disease and Atrial ...

Home November 18, 2020
Home
Feature | Heart Valve Technology
TAVR Is Now Dominant Form of Aortic Valve Replacement in the United States

November 17, 2020 — Since the approval of the first transcatheter aortic valve replacement (TAVR) device in 2011, more ...

Home November 17, 2020
Home
oston Scientific Corp. announced today it is immediately retiring the entire Lotus Edge transcatheter aortic valve replacement (TAVR) system. It also initiated a global, voluntary recall of all unused inventory of the Lotus Edge due to complexities associated with the product delivery system. 
Feature | Heart Valve Technology | Dave Fornell, Editor
Boston Scientific Pulls Lotus Edge TAVR Valve Off The Market

November 17, 2020 — Boston Scientific Corp. announced today it is immediately retiring the entire Lotus Edge ...

Home November 17, 2020
Home
Some of the device technologies discussed in the TCT 2020 late-breaking trial sessions. Top left, the  Medtronic Resolute Onyx stent was the first stent to receive FDA clearance for short duration dual-antiplatelet therapy, which was a big topic and subject of several sessions. Lower left, the Keystone TriGuard 3 TAVR embolic protection device did not demonstrate superiority over TAVR without use of embolic protection. Top right, the Abbott MitraClip. Acurate neo TAVR valve. #TCTconnect #TCT2020
Feature | TCT | Dave Fornell, Editor
Top 10 Takeaways on Interventional Technologies at TCT 2020

Here are some of the key takeaways from the late-breaking interventional cardiology and structural heart trials ...

Home October 29, 2020
Home
The Watchman FLX will be tested in the CHAMPION-AF trial looks at next-generation transcatheter LAA device as treatment alternative to NOACs for broader population of patients with non-valvular atrial fibrillation.
News | Atrial Fibrillation
Boston Scientific Initiates Trial to Evaluate Watchman FLX LAA Closure Device as First-Line Treatment

Oct. 29, 2020 — Boston Scientific initiated the CHAMPION-AF clinical trial to evaluate the safety and efficacy of the ...

Home October 29, 2020
Home
Videos | Heart Valve Technology
VIDEO: Results Mixed on Use of Cerebral Embolic Protection in TAVR From the STS/ACC TVT Registry

David Cohen, M.D., presents late-breaking data from the STS/ACC Transcatheter Valve Registry (TVT) showing the impact of ...

Home October 19, 2020
Home
Videos | Heart Valve Technology
VIDEO: General vs Local Anesthesia for TAVR Addressed in SOLVE-TAVI Trial

Doctor Hans-Josef Feistritzerm, Heart Center of Leipzig, Germany, presents data on the use of general vs. local ...

Home October 19, 2020
Home
Videos | Heart Failure
VIDEO: Use of MitraClip as a Bridge to Heart Transplant

The late-breaking MitraBridge Study was presented at Transcatheter Cardiovascular Therapeutics (TCT) 2020 meeting showed ...

Home October 16, 2020
Home
Positive clinical data from first-in-human studies of the Conformal Medical left atrial appendage closure (LAAC) CLAAS device performed in the U.S. and Prague were presented at 2020 Transcatheter Cardiovascular Therapeutics (TCT) Connect virtual meeting. Two two abstracts were presented by William Gray, M.D., from Lankenau Heart Institute, Wynnewood, Penn., and Vivek Reddy, M.D., from Mount Sinai Hospital in New York. #TCT2020 #TCTconnect
News | Left Atrial Appendage (LAA) Occluders
Conformal Medical CLAAS LAA Occluder Shows Promising Clinical Results at TCT 2020

October 16, 2020 — Positive clinical data from first-in-human studies of the Conformal Medical left atrial appendage ...

Home October 16, 2020
Home
The Keystone Heart TriGuard 3 (TG3) is a self-stabilizing cerebral embolic deflection filter used in patients undergoing transcatheter aortic valve replacement (TAVR). The device is designed to reduce TAVR complications of cerebral embolization and ischemic stroke. #TCT #TCT2020 #TCTconnect
News | Heart Valve Technology
Keystone Heart TAVR Embolic Protection Device Did Not Demonstrate Superiority 

October 15, 2020 – The REFLECT II randomized clinical trial evaluating the safety and efficacy of the Keystone Heart ...

Home October 15, 2020
Home
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now